World-Class Drug
Development Capabilities
Program
Indication
Discovery
In Vitro
In Vivo
Preclinical
Lead Op
IND Enabling
Clinical
Stage 1
Stage 2
Stage 3
Global Rights
PLN-74809
Dual selective inhibitor of
αvβ6/αvβ1
WHOLLY OWNED
Idiopathic Pulmonary Fibrosis (IPF)
Primary Sclerosing Cholangitis (PSC)
COVID-19 - Related ARDS
PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC.
While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.
PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC.
While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.
αvβ6 can be upregulated in the lungs of COVID-19 patients where it activates TGF-β. High levels of active TGF-β cause a number of dangerous effects including inflammation, epithelial cell death, infiltration of fluid into the lungs and fibrosis, collectively leading to acute respiratory distress syndrome (ARDS).
Oncology
Inhibitor of αvβ8
Solid Tumors
Our oncology program focuses on selective inhibition of αvβ8, an integrin that can activate TGF-β in the tumor microenvironment, causing an anti-inflammatory effect and potential resistance to immuno-oncology therapeutics such as checkpoint inhibitors.
Muscular Dystrophy
Anti-integrin mAb
Other Muscular Dystrophies
Muscular dystrophy comprises a group of inherited diseases, all characterized by inborn errors in dystrophin, a protein that anchors muscle cells to the extracellular matrix and facilitates contraction. The lack of dystrophin results in muscle cell damage upon contraction, causing a progressive loss of muscle function over time.
PLN-1474
Selective inhibitor of αvβ1
PARTNERED
NASH-Associated Liver Fibrosis
Our second product candidate, PLN-1474, is a small-molecule selective inhibitor of αvβ1 for the treatment of late stage liver fibrosis associated with nonalcoholic steatohepatitis (NASH). The integrin αvβ1 activates TGF-β in the liver, leading to fibrosis and, potentially, liver failure.
Expanding Possibilities
We are evaluating the potential benefits of our product candidates outside of their lead indications. Our product candidates have shown anti-fibrotic activity in multiple animal models as well as live human tissues in indications outside of IPF, PSC, and NASH. We will continue to evaluate additional indications to maximize the potential of our pipeline.